Annals of Optometry and Contact Lens 2018;17(4):83-88.
Published online December 25, 2018.
미숙아망막병증 진단과 치료의 최신 지견
허 환
전남대학교 의과대학 안과학교실
Update on Diagnosis and Treatment of Retinopathy of Prematurity
Hwan Heo
Department of Ophthalmology, Chonnam National University Medical School, Gwangju, Korea
Received: 24 October 2018   • Revised: 8 December 2018   • Accepted: 8 December 2018
Retinopathy of prematurity is still the leading cause of blindness in children. It is on the rise due to the development of postnatal care technology in developing and developed countries. However, due to the lack of experts, appropriate diagnosis and treatment are often not available. Therefore, it is necessary to develop technologies such as telemedicine and diagnostic automation technology for retinopathy of prematurity. Experts should know that the difference of timing and nature of recurrence between intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection and laser treatment. And, after verifying safety dose and systemic complication, guidelines for safe use of intravitreal anti-VEGF injection should be developed.
Key Words: Bevacizumab; Ranibizumab; Retinopathy of prematurity; Telemedicine

Editorial Office
Korea University Anam Hospital, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea
Tel: +82-2-2271-6603    Fax: +82-2-2277-5194    E-mail:                

Copyright © 2023 by The Korean Optometry Society and The Korean Contact Lens Study Society.

Developed in M2PI

Close layer
prev next